Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
October 09, 2024 06:30 ET
|
Clearside Biomedical, Inc.
- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not...
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
August 27, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector® - - Topline Data Expected to be Reported During the Week of October...
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
June 12, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ...
Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
February 08, 2024 15:17 ET
|
Spherix Global Insights
Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...
Wet-Age Related Macular Degeneration Market to Observe Stupendous Growth by 2032, Predicts DelveInsight | Key Players - AbbVie, Opthea, AffaMed Therapeutics, EyeBiotech, Novartis, Hoffmann-La Roche, Kyowa Kirin, Skyline Therapeutics
January 31, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Wet-Age Related Macular Degeneration Market to Observe Stupendous Growth by 2032, Predicts DelveInsight | Key Players - AbbVie, Opthea, AffaMed...
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
December 14, 2023 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
December 04, 2023 15:46 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
November 19, 2023 23:19 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
November 16, 2023 14:09 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
November 02, 2023 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical announced that multiple oral & poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Mtg.